Millennium Management LLC has filed an amendment to its Schedule 13G, revealing a significant reduction in its stake in RxSight, Inc. The filing indicates that Millennium now holds less than 5% of the common stock of the ophthalmic goods company, a notable shift from its previous ownership levels.

This change is important as it highlights a strategic adjustment by Millennium Management, a prominent player in the investment management sector. The reduction in ownership could reflect broader trends in the ophthalmic goods industry, where competition and market dynamics are constantly evolving.

Background

Millennium Management LLC, incorporated in Delaware, is a well-known investment management firm. It has been active in various sectors, including healthcare and technology. The firm has a history of filing numerous Schedule 13G forms, indicating its investment activities and ownership stakes in various companies.

What the Filing Says

The latest filing, dated November 2, 2026, states that Millennium Management has ceased to beneficially own more than 5% of RxSight, Inc. Specifically, it reports shared voting and dispositive power over 2,142,052 shares, which constitutes approximately 5.1% of the company's common stock.

Impact

This reduction in stake may affect the perception of RxSight, Inc. among investors and analysts. As a significant hedge fund, Millennium's investment decisions can influence market sentiment and investor confidence in the ophthalmic goods sector.

What's Next

The filing does not say what happens next.